Mr. Kazo is the President and COO of Prolong Pharmaceuticals and brings over 20 years of experience in the biopharmaceutical and medical device industries as an industry leader, senior executive, corporate officer, and scientist with extensive business development, strategic planning, marketing, and financing experience in the global health arena. He has been responsible for raising over $300 million in capital from international investors, including a leading role in three successful IPOs.
Glenn was a founding member of Enzon, Inc., where he built and managed the business development and licensing group. As Enzon’s Vice President of Sales and Marketing, Mr. Kazo launched the company’s first two products. Subsequently, Glenn joined Focal, Inc. (now a unit of Genzyme Corporation) and helped take the biomaterials company public. Glenn became US General Manager and Board member at XTL Biopharmaceuticals, Inc., which listed on the primary London Stock Exchange during his tenure. Glenn then became Chief Business Officer at Activbiotics, Inc., a venture capital-backed anti-infective/cardiovascular company.
Mr. Kazo has served as Director on several biotech company boards including XTL, Prolong Pharmaceuticals, LLC, and iviGene corporation, now a unit of Oragenics, Inc.. Throughout his career, Glenn has continued an active consulting practice via Kazo Associates, advising biopharma clients and venture capital firms on corporate strategy and development.